Sugi Predict

Sugi Predict / Compounds / SCHEMBL833441

SCHEMBL833441

SCHEMBL833441

CC(C)(C)OC(=O)N1C[CH]CCC1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.47
▸ USP2 O75604 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ EPHX1 P07099 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ PREP P48147 1/20 0.40
▸ GPR119 Q8TDV5 1/20 0.39
▸ ESR2 Q92731 1/20 0.39
▸ CTSK P43235 1/20 0.39
▸ RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4504907 0.95 HPGD (0.50) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL294179 0.89 USP2 (0.50) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL2197203 0.86 USP2 (0.51) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL4693378 0.84 HPGD (0.46) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL1242684 0.81 USP2 (0.52) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL772117 0.79 CYP1A2 (0.41) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL15624132 0.79 HPGD (0.49) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL15624147 0.79 HPGD (0.49) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL15624094 0.79 USP2 (0.51) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL11913651 0.79 USP2 (0.51) HPGDUSP2SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348453-A1 HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2023-11-02 — — US claimed
CN-115667255-A Halogenated heteroaryl and other heterocyclic kinase inhibitors and uses thereof 艾欧麦克斯治疗股份公司 2023-01-31 — — CN claimed
US-20210387982-A1 HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2021-12-16 — — US claimed
CN-108640965-B 2-substituted-18 beta-glycyrrhetinic acid derivative and application thereof 沈阳药科大学 2021-11-05 — — CN claimed
CN-112955447-A Heterocyclic kinase inhibitors and uses thereof 艾欧麦克斯治疗股份公司 2021-06-11 — — CN claimed
EP-3643713-A1 HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF iOmx Therapeutics AG (DE) 2020-04-29 — — EP claimed
EP-3363788-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2018-08-22 — — EP claimed
EP-2909193-B1 PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T JANSSEN PHARMACEUTICA NV (BE) 2017-04-19 — — EP claimed
US-9309222-B2 Phenyl linked quinolinyl modulators of RORγt JANSSEN PHARMACEUTICA NV (BE) 2016-04-12 — — US claimed
US-9227955-B2 Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same BORYUNG PHARMACEUTICAL CO., LTD. (KR) 2016-01-05 — — US claimed
WO-2010136817-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-12-02 — — WO claimed
US-7566716-B2 Imidazopyrazines as Raf inhibitor compounds ARRAY BIOPHARMA INC. (US) 2009-07-28 — — US claimed
US-20090099160-A1 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors ASTRAZENECA AB (SE) 2009-04-16 — — US claimed
EP-1935882-A1 Bicyclic compounds Asahi Kasei Pharma Corporation (JP) 2008-06-25 — — EP claimed
EP-1902056-A2 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2008-03-26 — — EP claimed
US-20060281751-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA, INC. 2006-12-14 — — US claimed
WO-2006125101-A2 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2006-11-23 — — WO claimed
EP-1689720-A1 PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS Aventis Pharma S.A. (FR) 2006-08-16 — — EP claimed
WO-2005051917-A9 PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS AVENTIS PHARMA SA (FR) 2005-09-29 — — WO claimed
WO-2005051917-A1 PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS AVENTIS PHARMA S.A. (FR) 2005-06-09 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099160-A1 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors CCNI, CDK4, CDK3 HPGD 1514/4885USP2 2476/4885SMN1; SMN2 1922/4885
US-20060281751-A1 Raf inhibitor compounds and methods of use thereof BRAF, RAF1, ARAF HPGD 2340/4885USP2 2505/4885SMN1; SMN2 1831/4885
US-20210387982-A1 HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF LCK, SRC, CILK1 HPGD 3917/4885USP2 2690/4885SMN1; SMN2 1709/4885
US-20230348453-A1 HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF ABL1, PRKDC, PRKACA HPGD 4581/4885USP2 2456/4885SMN1; SMN2 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.